J

Johnson & Johnson

Makes prescription drugs and medical devices

IDAR Summer Intern - DM CM

Summer 2027Deadline 11/9/26
$23.50 - $52.50/hr+ Pension plan
Internship
Bachelor's
Spring House, PA, USA+2 moreMore locations: Raritan, NJ, USA | Hopewell Township, NJ, USA
Hybrid
Biology & BiotechClinical Research Operations
No H1B Sponsorship

About the job

Requirements
  • Completion of undergraduate freshman year at an accredited university is required.
  • Currently pursuing a bachelor's degree in science (Biology, Chemistry, Biochemistry, Neuroscience, Pharmacology, and others), Data and/or Computer Science, Statistics, Analytics, Mathematics, IT and Systems, or related fields.
  • Have a cumulative GPA of 3.5 or higher, reflective of all college coursework.
  • Candidates must be enrolled in an undergraduate university program at the time of the internship and must not graduate during the internship period.
  • Ability to work within the designated hybrid model, including three days at a local New Jersey or Pennsylvania site and two days remotely.
  • Candidates are responsible for transportation to the applicable local site.
  • Ability to work effectively within established processes, procedures, policies, and regulatory requirements.
  • Must be permanently authorized to work in the United States and must not require employment visa sponsorship, including H-1B or green card sponsorship, at the time of application or in the future. Students on CPT, OPT, or STEM OPT generally do not meet this requirement unless eligible for an alternative long-term status that does not require company sponsorship.
  • Candidates under 18 may need to obtain work papers or other documentation required by state law and parental consent for the background check.
Responsibilities
  • Execute assigned clinical trial activities within the scope of the internship.
  • Perform activities in compliance with applicable company and Data Management and Central Monitoring standard operating procedures, processes, policies, training requirements, Good Clinical Practice, and applicable regulatory requirements.
  • Collaborate with colleagues within Data Management and Central Monitoring and other cross-functional partners.
  • Support innovation and process improvement projects as assigned.
  • Contribute to projects aligned with strategic priorities and company values.
  • For the Clinical Data Manager assignment, support scientific clinical study data review activities.
  • For the Clinical Data Manager assignment, assist with management and resolution of Study Responsible Scientist and Study Responsible Physician queries within Electronic Data Capture systems.
  • For the Clinical Data Manager assignment, support additional clinical data review activities, including coding and Serious Adverse Event reconciliation.
  • For the Data Acquisition Expert-EDC assignment, support setup and maintenance of Electronic Data Capture systems for assigned clinical trials.
  • For the Data Acquisition Expert-EDC assignment, support Electronic Data Capture activities according to established best practices and guidelines.
  • For the Data Acquisition Expert-EDC assignment, gain exposure to clinical technology platforms such as Medidata Rave.
Desired Qualifications
  • Experience or exposure to data review, data analysis, or data quality activities.
  • Experience or familiarity with technology platforms and systems used for the collection, management, analysis, or reporting of data.
  • Familiarity with Electronic Data Capture systems or clinical data management technologies.
  • Exposure to Medidata Rave or similar clinical data platforms.
  • Interest in clinical trials, clinical data management, data acquisition, or pharmaceutical drug development.
  • Strong analytical and problem-solving skills with attention to detail.
  • Excellent written and verbal communication and presentation skills.
  • Ability to manage multiple assignments and priorities while delivering results.
  • Ability to work independently as a self-starter while contributing effectively to team objectives.
  • Demonstrated leadership or participation in academic programs, campus organizations, or community service activities.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
The Irish Times
Oct 28th, 2026
Johnson & Johnson buys Irish stroke care firm in multimillion euro deal

Sale of Neuravi is largest deal for a venture-backed medtech in Europe since 2009

Associated Press
Oct 27th, 2026
Pomerantz investigates Johnson & Johnson after 5.73% share drop on talc charges and MedTech miss

Pomerantz LLP is investigating whether Johnson & Johnson (J&J) and some of its officers or directors engaged in securities fraud or other unlawful business practices. The law firm advises affected investors to contact Danielle Peyton at [email protected]. On October 13, 2026, J&J reported third-quarter GAAP net earnings of $210 million, or $0.09 per share. Multi-billion dollar special charges tied to its talc litigation settlement weighed on the result. Its MedTech segment grew only 2.5% to $8.64 billion, a second straight revenue miss. J&J cited pricing constraints in China and disruption in the Middle East. The stock fell $15.12, or 5.73%, to close at $248.61 that day.

Yahoo Finance
Oct 27th, 2026
J&J sees $34.7M net ETF outflow, extending selling streak to four days

ETFs sold a net $34.7 million of Johnson & Johnson stock on Friday, October 23, extending a four-day run of net selling. SPY led the move, cutting $34.6 million, or 0.44% of its stake. XLV sold $24.6 million and DIA $6.3 million. More funds bought than sold, with 26 ETFs adding shares and 17 cutting them, but their purchases were smaller. Net outflows were $55.2 million on October 22, $54.1 million on October 21, and $19.8 million on October 20. A net inflow of $38.1 million came on October 19. Johnson & Johnson has a market cap of $641.1 billion. It reported $99.35 billion in trailing-12-month revenue, up 7.0% over one year.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.